The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 18 September, 2015 by The TZ Newswire Staff

The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech

Big Pharma and biotech valuations have taken a hit during this correction, but they could have something more pressing to worry about now that valuations are on the decline.

See also
- Next Article Volkswagen ordered to recall nearly 500K vehicles
- Previous Article Buiter: Migrant Crisis "May Signal The Beginning Of The End" For EU
Editorial Calender

September 2015

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30

« Aug Oct »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 18 September, 2015 by The TZ Newswire Staff

The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech

See also

Editorial Calender

Recent Tags